Thank you, Mr. Chair.
Thanks to all of you for being here today. We greatly appreciate it.
I was hoping that Dr. Bonn-Miller would still be here. I had a couple of questions for him, but perhaps some of you might be able to answer them as we go through this.
Obviously, without research, we end up having no guidelines and no standards. We don't know the prescription levels to be used. We don't know the strengths—or the strains, as we've just heard—as to what's to be used along those lines. One of Dr. Bonn-Miller's comments was that he believed the pharmaceutical companies need to be funding a lot of this research. To me, that type of study design has a huge bias. With that bias, you lose validity and you lose all sorts of intrinsic issues.
I'll start with you, Dr. Walsh, and then maybe Dr. Thirlwell can comment on that, as well as Max.